Table 1 Clinicopathological characteristics of patients and tumors in SCAN-B divided by screening subpopulation
Non-screened patients (n = 5760) | Screened patients (n = 900) | Total (n = 6660) | P | |
|---|---|---|---|---|
Gender | < 0.001 | |||
Female | 5732 (99.5%) | 880 (97.8%) | 6612 (99.3%) | |
Male | 28 (0.5%) | 20 (2.2%) | 48 (0.7%) | |
Age at diagnosis (years) | < 0.001 | |||
≤ 40 | 117 (2.0%) | 212 (23.6%) | 329 (4.9%) | |
41–50 | 830 (14.4%) | 214 (23.8%) | 1044 (15.7%) | |
51–60 | 1140 (19.8%) | 157 (17.4%) | 1297 (19.5%) | |
61–70 | 1850 (32.1%) | 205 (22.8%) | 2055 (30.9%) | |
71–80 | 1228 (21.3%) | 87 (9.7%) | 1315 (19.7%) | |
≥ 81 | 595 (10.3%) | 25 (2.8%) | 620 (9.3%) | |
Nottingham histologic grade (NHG) | < 0.001 | |||
Grade 1 | 923 (16.0%) | 103 (11.4%) | 1026 (15.4%) | |
Grade 2 | 2824 (49.0%) | 361 (40.1%) | 3185 (47.8%) | |
Grade 3 | 1820 (31.6%) | 332 (36.9%) | 2152 (32.3%) | |
Not available | 193 (3.4%) | 104 (11.6%) | 297 (4.5%) | |
Tumor size | 0.68 | |||
T1 (< 20 mm) | 3329 (57.8%) | 547 (60.8%) | 3876 (58.2%) | |
T2 (20–50 mm) | 1743 (30.3%) | 267 (29.7%) | 2010 (30.2%) | |
T3 (> 50 mm) | 169 (2.9%) | 27 (3.0%) | 196 (2.9%) | |
Other/Not available | 519 (9.0%) | 59 (6.6%) | 578 (8.7%) | |
Ki67 status | < 0.001 | |||
Low | 2890 (50.2%) | 341 (37.9%) | 3231 (48.5%) | |
High | 2870 (49.8%) | 559 (62.1%) | 3429 (51.5%) | |
Risk of recurrence (ROR) score | < 0.001 | |||
Low | 1937 (33.6%) | 241 (26.8%) | 2178 (32.7%) | |
Intermediate | 1287 (22.3%) | 174 (19.3%) | 1461 (21.9%) | |
High | 2329 (40.4%) | 433 (48.1%) | 2762 (41.5%) | |
Not available | 207 (3.6%) | 52 (5.8%) | 259 (3.9%) | |
Clinical subgroup | < 0.001 | |||
ER + /HER2 − /LN − | 2869 (49.8%) | 328 (36.4%) | 3197 (48.0%) | |
ER + /HER2 − /LN + | 1495 (26.0%) | 232 (25.8%) | 1727 (25.9%) | |
HER2 + /ER − | 221 (3.8%) | 33 (3.7%) | 254 (3.8%) | |
HER2 + /ER + | 469 (8.1%) | 95 (10.6%) | 564 (8.5%) | |
TNBC | 489 (8.5%) | 160 (17.8%) | 649 (9.7%) | |
Not available | 217 (3.8%) | 52 (5.8%) | 269 (4.0%) | |
PAM50 molecular subtype (restricted by ER/HER2 status) | < 0.001 | |||
Luminal A (& ER + /HER2 −) | 2904 (50.4%) | 359 (39.9%) | 3263 (49.0%) | |
Luminal B (& ER + /HER2 −) | 1173 (20.4%) | 155 (17.2%) | 1328 (19.9%) | |
HER2-enriched (& HER2 +) | 337 (5.9%) | 53 (5.9%) | 390 (5.9%) | |
Basal (& ER − /HER2 −) | 338 (5.9%) | 143 (15.9%) | 481 (7.2%) | |
Other | 1008 (17.5%) | 190 (21.1%) | 1198 (18.0%) | |